Perrigo Company plc (NYSE:PRGO) Director Katherine C. Doyle Sells 8,954 Shares

Perrigo Company plc (NYSE:PRGO) Director Katherine C. Doyle sold 8,954 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the sale, the director now owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Perrigo Stock Up 2.2 %

Shares of Perrigo stock opened at $27.75 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.24. Perrigo Company plc has a 1-year low of $24.82 and a 1-year high of $34.60. The business’s fifty day moving average price is $27.83 and its two-hundred day moving average price is $28.74. The company has a market capitalization of $3.78 billion, a P/E ratio of -396.43 and a beta of 0.49.

Perrigo (NYSE:PRGO) last announced its earnings results on Friday, August 2nd. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Perrigo had a negative net margin of 2.81% and a positive return on equity of 6.79%. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the firm posted $0.63 EPS. Perrigo’s revenue was down 10.7% compared to the same quarter last year. As a group, research analysts forecast that Perrigo Company plc will post 2.57 EPS for the current year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th will be paid a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date of this dividend is Friday, August 30th. Perrigo’s payout ratio is currently -1,571.43%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PRGO shares. Piper Sandler dropped their price objective on shares of Perrigo from $36.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Monday, August 5th.

Institutional Trading of Perrigo

Several institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new stake in Perrigo during the second quarter valued at approximately $213,000. Systematic Financial Management LP boosted its stake in shares of Perrigo by 0.3% during the 2nd quarter. Systematic Financial Management LP now owns 1,135,821 shares of the company’s stock worth $29,168,000 after acquiring an additional 3,545 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Perrigo during the second quarter worth $351,000. Clearline Capital LP lifted its holdings in shares of Perrigo by 17.0% during the second quarter. Clearline Capital LP now owns 1,830,419 shares of the company’s stock valued at $47,005,000 after purchasing an additional 265,960 shares during the last quarter. Finally, Scientech Research LLC acquired a new position in shares of Perrigo in the 2nd quarter valued at $629,000. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.